Amerigen Pharmaceuticals Limited and Stason Pharmaceuticals Inc. announced they has entered into a collaboration agreement regarding the development of generic oral oncology products. Under the terms of the agreement, Stason will use its specialized containment facilities and formulation expertise to develop and manufacture products for Amerigen to commercialize in the United States and other territories. Stason received an up-front fee and is eligible for additional product-specific development milestones, plus manufacturing revenues and royalties on any commercialized products.

“This deal allows Amerigen to broaden the range of specialty oral products within its development portfolio,” said Jonathan Embleton, Chief Business Officer for Amerigen. “We look forward to working with Stason to bring generic versions of some important critical care products to market and we are especially pleased to announce the concurrent filing of the first ANDA from this collaboration.”

“We have been working hard to leverage our high containment development and manufacturing capabilities,” said Jim Fang, chief operating officer for Stason. “This opportunity allows Stason to fully develop and commercialize our pipeline of generic oral oncology products. We look forward to working with Amerigen to accomplish this goal.”

Amerigen Pharmaceuticals is a group of companies engaged in all phases of the generic pharmaceutical business, with operations in the US and China.

Stason Pharmaceuticals Inc. is involved in the development and manufacture of oral pharmaceuticals products.